Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician's guide
BC Simes, GG MacGregor - Diabetes, metabolic syndrome and …, 2019 - Taylor & Francis
This comprehensive review covers the historical background, physiology, application in type
2 diabetes, novel uses, cardiovascular benefits, side effects and contraindications of sodium …
2 diabetes, novel uses, cardiovascular benefits, side effects and contraindications of sodium …
Heart failure with preserved ejection fraction diagnosis and treatment: an updated review of the evidence
MG Del Buono, G Iannaccone, R Scacciavillani… - Progress in …, 2020 - Elsevier
Over the last several decades, clinicians and clinical scientists have had growing interest in
heart failure (HF) diagnosis and treatment. While HF with reduced ejection fraction (EF) is a …
heart failure (HF) diagnosis and treatment. While HF with reduced ejection fraction (EF) is a …
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with …
S Hiruma, F Shigiyama, S Hisatake, S Mizumura… - Cardiovascular …, 2021 - Springer
Background While the cardioprotective benefits of sodium-glucose cotransporter-2 (SGLT2)
inhibitors have been established in patients with cardiovascular disease (CVD), their …
inhibitors have been established in patients with cardiovascular disease (CVD), their …
Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure
H Nambu, S Takada, A Fukushima, J Matsumoto… - European Journal of …, 2020 - Elsevier
Decreased exercise capacity, which is an independent predictor of the poor prognosis of
patients with heart failure (HF), is attributed to markedly impaired skeletal muscle …
patients with heart failure (HF), is attributed to markedly impaired skeletal muscle …
Could SGLT2 inhibitors improve exercise intolerance in chronic heart failure?
SN Voorrips, H Saucedo-Orozco… - International Journal of …, 2022 - mdpi.com
Despite the constant improvement of therapeutical options, heart failure (HF) remains
associated with high mortality and morbidity. While new developments in guideline …
associated with high mortality and morbidity. While new developments in guideline …
The importance of SGLT-2 inhibitors as both the prevention and the treatment of diabetic cardiomyopathy
K Kowalska, P Wilczopolski, D Buławska, E Młynarska… - Antioxidants, 2022 - mdpi.com
According to the 2021 report of the International Diabetes Federation (IDF), there have been
approximately 573 million cases of type 2 diabetes mellitus (T2DM) among adults, which …
approximately 573 million cases of type 2 diabetes mellitus (T2DM) among adults, which …
The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA …
Background Canagliflozin reduces hospitalizations for heart failure (HF) in type 2 diabetes
mellitus (T2DM). Its effect on cardiorespiratory fitness and cardiac function in patients with …
mellitus (T2DM). Its effect on cardiorespiratory fitness and cardiac function in patients with …
The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis
Y Peng, D Qin, Y Wang, L Xue, YX Qin, X Xu - Frontiers in Physiology, 2023 - frontiersin.org
Objective: The study aimed to evaluate the effect of sodium–glucose transporter 2 (SGLT-2)
inhibitors on various parameters of exercise capacity and provide an evidence-based basis …
inhibitors on various parameters of exercise capacity and provide an evidence-based basis …
Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies
AK Singh, R Singh - Expert Review of Clinical Pharmacology, 2019 - Taylor & Francis
Introduction: Heart failure (HF) in type 2 diabetes mellitus (T2DM) poses a significant
increase in mortality. Until recently, anti-diabetic drugs have not been shown to reduce …
increase in mortality. Until recently, anti-diabetic drugs have not been shown to reduce …
Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT‐2 inhibitors and GLP‐1 receptor agonists
Patients with type 2 diabetes mellitus (T2D) present an increased risk for cardiovascular
(CV) complications. In addition to improvement in glycaemic control, glucose‐lowering …
(CV) complications. In addition to improvement in glycaemic control, glucose‐lowering …